In Vivo Base Editing of PCSK9 with VERVE

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-07-21 • Permanent link

In a groundbreaking study published in the New England Journal of Medicine, researchers from the University of California, San Francisco, have successfully demonstrated the in vivo base editing of PCSK9 with VERVE, a novel gene editing tool. This breakthrough achievement marks a significant milestone in the development of gene editing technologies, with potential applications in the treatment of genetic disorders. The study involved a team of scientists led by Dr. Jennifer Doudna, a renowned expert in RNA-based gene editing, who used VERVE to edit the PCSK9 gene in mice, resulting in a 90% reduction in cholesterol levels. The market reaction was immediate, with shares of biotech companies involved in the study surging in value.

The implications of this technology are far-reaching, with the potential to revolutionize the treatment of genetic diseases. PCSK9 is a gene that plays a critical role in cholesterol metabolism, and high levels of PCSK9 have been linked to an increased risk of cardiovascular disease. By editing the PCSK9 gene, researchers hope to develop new treatments for conditions such as familial hypercholesterolemia, a genetic disorder that affects millions of people worldwide. Investors are taking notice, with biotech companies such as CRISPR Therapeutics and Regeneron Pharmaceuticals seeing significant gains in value.

The development of gene editing technologies like VERVE is a culmination of decades of research in the field of molecular biology. The discovery of the CRISPR-Cas9 system by Jennifer Doudna and Emmanuelle Charpentier in 2012 marked a major breakthrough in the field, and since then, numerous researchers have been working to develop new gene editing tools. VERVE, in particular, has been hailed as a more precise and efficient alternative to CRISPR-Cas9, with the potential to be used in a wider range of applications.

As researchers continue to refine and expand the use of VERVE, the potential for this technology to transform the treatment of genetic diseases is vast. However, there are also risks associated with this technology, including the potential for off-target effects and unintended consequences. In the coming months, investors will be watching closely for updates on the development of VERVE, including clinical trials and regulatory approvals. With the potential to revolutionize the treatment of genetic diseases, VERVE is an area that is sure to be closely followed in the months and years to come.